Literature DB >> 16265019

Treatment endpoints for advanced cholangiocarcinoma.

Gregory J Gores1, Edwina S Baskin-Bey, Todd H Baron, Steven R Alberts.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 16265019     DOI： 10.1038/ncpgasthep0008

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN： 1743-4378


× No keyword cloud information.
  2 in total

1.  Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.

Authors:  A D Wagner; P Buechner-Steudel; M Moehler; H Schmalenberg; R Behrens; J Fahlke; A Wein; S Behl; O Kuss; G Kleber; W E Fleig
Journal:  Br J Cancer       Date:  2009-11-10       Impact factor: 7.640

2.  Beclin 1 deficiency correlated with lymph node metastasis, predicts a distinct outcome in intrahepatic and extrahepatic cholangiocarcinoma.

Authors:  Tian-Tian Wang; Qing-Hua Cao; Ming-Yuan Chen; Qing Xia; Xin-Juan Fan; Xiao-Kun Ma; Qu Lin; Chang-Chang Jia; Min Dong; Dan-Yun Ruan; Ze-Xiao Lin; Jing-Yun Wen; Li Wei; Xing Li; Zhan-Hong Chen; Lei Wang; Xiang-Yuan Wu; Xiang-Bo Wan
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.